These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 3041238)
1. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. Kerrigan D; Pommier Y; Kohn KW NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238 [TBL] [Abstract][Full Text] [Related]
2. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Ross W; Rowe T; Glisson B; Yalowich J; Liu L Cancer Res; 1984 Dec; 44(12 Pt 1):5857-60. PubMed ID: 6094001 [TBL] [Abstract][Full Text] [Related]
3. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377 [TBL] [Abstract][Full Text] [Related]
4. Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines. Dorr RT; Liddil JD; Gerner EW Cancer Res; 1986 Aug; 46(8):3891-5. PubMed ID: 3015379 [TBL] [Abstract][Full Text] [Related]
5. Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization. Gewirtz DA; Ellis AL; Randolph JK; Yanovich S; Swerdlow PS; Povirk LF; Yalowich JC Cancer Commun; 1989; 1(3):175-80. PubMed ID: 2561738 [TBL] [Abstract][Full Text] [Related]
6. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888 [TBL] [Abstract][Full Text] [Related]
7. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Yalowich JC; Ross WE Cancer Res; 1984 Aug; 44(8):3360-5. PubMed ID: 6744270 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540 [TBL] [Abstract][Full Text] [Related]
9. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148 [TBL] [Abstract][Full Text] [Related]
10. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Wolverton JS; Danks MK; Schmidt CA; Beck WT Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902 [TBL] [Abstract][Full Text] [Related]
11. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Sullivan DM; Latham MD; Ross WE Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304 [TBL] [Abstract][Full Text] [Related]
12. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Yang L; Rowe TC; Liu LF Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA. Woynarowski JM; Sigmund RD; Beerman TA Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925 [TBL] [Abstract][Full Text] [Related]
14. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines. Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282 [TBL] [Abstract][Full Text] [Related]
15. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166 [TBL] [Abstract][Full Text] [Related]
16. Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide). Lönn U; Lönn S; Nylen U; Winblad G Cancer Res; 1989 Nov; 49(22):6202-7. PubMed ID: 2553248 [TBL] [Abstract][Full Text] [Related]
17. Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells. Vietti TJ; Valeriote FA; Kalish R; Coulter D Cancer Treat Rep; 1978 Sep; 62(9):1313-20. PubMed ID: 688275 [TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Pommier Y; Orr A; Kohn KW; Riou JF Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259 [TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines. Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]